NuVasive, Inc.

$39.75-2.24%($-0.91)
TickerSpark Score
64/100
Mixed
73
Valuation
70
Profitability
80
Growth
68
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NUVA research report →

52-Week Range32% of range
Low $35.17
Current $39.75
High $49.53

Companywww.nuvasive.com

NuVasive, Inc. , a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment.

CEO
J. Christopher Barry
IPO
2004
Employees
3,000
HQ
San Diego, CA, US

Price Chart

-13.94% · this period
$49.34$42.51$35.68Sep 08Mar 10Sep 08

Valuation

Market Cap
$2.08B
P/E
56.43
P/S
1.73
P/B
2.62
EV/EBITDA
19.11
Div Yield
0.00%

Profitability

Gross Margin
72.00%
Op Margin
5.39%
Net Margin
3.36%
ROE
4.86%
ROIC
2.54%

Growth & Income

Revenue
$1.20B · 5.53%
Net Income
$40.41M · 163.05%
EPS
$0.78 · 162.90%
Op Income
$64.77M
FCF YoY
-57.41%

Performance & Tape

52W High
$49.53
52W Low
$35.17
50D MA
$40.83
200D MA
$41.23
Beta
1.07
Avg Volume
1.41M

Get TickerSpark's AI analysis on NUVA

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Sep 1, 23Wolterman Dansell4,816
Sep 1, 23Raimundo Amy Beltsell4,816
Sep 1, 23Norwalk Leslie Vsell3,095
Sep 1, 23Norwalk Leslie Vsell4,816
Sep 1, 23Kadia Siddharthasell4,816
Sep 1, 23Kadia Siddharthasell3,739
Sep 1, 23Huennekens R Scottsell4,816
Sep 1, 23Huennekens R Scottsell1,360
Sep 1, 23FRIEL ROBERT Fsell4,816
Sep 1, 23DeFord John Asell3,788

Our NUVA Coverage

We haven't published any research on NUVA yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate NUVA Report →

Similar Companies